Impact of Postoperative Chemotherapy on Survival in Patients with Primary Central Nervous System Lymphoma: A Study Based on the SEER Database

被引:0
|
作者
Chen, Yushan [1 ,2 ]
Zheng, Shuishun [3 ]
Zheng, Shunyong [1 ]
Lin, Hong [3 ]
Wei, Lizhen [1 ]
Chen, Shaoqiang [4 ]
机构
[1] Zhangzhou Hosp, Imaging Dept, Zhangzhou, Fujian, Peoples R China
[2] Fujian Med Univ, Imaging Dept, Zhangzhou Affiliated Hosp, Zhangzhou, Fujian, Peoples R China
[3] Zhangzhou Hosp, Neurosurg Dept, Zhangzhou, Fujian, Peoples R China
[4] Fujian Med Univ, Sch Basic Med Sci, Fuzhou, Fujian, Peoples R China
关键词
postoperative chemotherapy; overall survival; primary central nervous system lymphoma; SEER; HIGH-DOSE METHOTREXATE; PRIMARY CNS LYMPHOMA; MALIGNANT-LYMPHOMA; PROGNOSTIC MODEL; EPIDEMIOLOGY; SURVEILLANCE; MANAGEMENT; RITUXIMAB; DIAGNOSIS; THERAPY;
D O I
10.12968/hmed.2024.0243
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/Background We aimed to investigate the impact of postoperative chemotherapy (POCT) on survival in patients with primary central nervous system lymphoma (PCNSL) using data from the Surveillance, Epidemiology, and End Results (SEER) database. Methods This study included 786 PCNSL patients, of which 605 received chemotherapy after surgery, and 181 did not. Data from the SEER registry database (2007-2020) were used to analyze PCNSL. Baseline information, including age, sex, race, marital status, primary tumour site, histological type, summary stage, surgical procedures, chemotherapy, and radiotherapy, was analyzed. Propensity Score Matching (PSM) (1:1) was employed to balance the effects of confounding variables between the two groups. Subsequently, Cox regression and bidirectional stepwise regression were used to identify independent prognostic factors. Kaplan-Meier (K-M) survival curves were constructed to assess the impact of POCT on patient prognosis. Additionally, two cases of PCNSL with typical magnetic resonance imaging appearances were presented. Results Multivariate Cox regression results revealed that age older than 60 years (hazard ratio [HR] = 1.786; 95% confidence interval [CI]: 1.272-2.509; p = 0.001) and absence of POCT (HR = 2.841; 95% CI: 2.159-3.738; p < 0.001) were independent prognostic risk factors, while primary tumour locations in the meninges (HR = 0.136; 95% CI: 0.032-0.569; p = 0.006) and other nervous system regions (HR = 0.552; 95% CI: 0.326-0.936; p = 0.027), as well as histological morphologies such as diffuse large B-cell lymphoma (HR = 0.233; 95% CI: 0.128-0.425; p < 0.001) and non-Hodgkin lymphoma (HR = 0.559; 95% CI: 0.356-0.876; p = 0.011), were associated with favourable patient outcomes. K-M curves demonstrated that the group undergoing POCT had a significantly more favourable prognosis compared to the non-POCT group, before (HR = 0.454; 95% CI: 0.343-0.600; p < 0.0001) or after PSM (HR = 0.580; 95% CI: 0.431-0.780; p < 0.0001). For patients with PCNSL, those with tumours located in the infratentorial region (HR = 0.231; 95% CI: 0.078-0.682; p = 0.046), supratentorial region (HR = 0.250; 95% CI: 0.163-0.383; p < 0.0001), overlapping brain regions (HR = 0.201; 95% CI: 0.056-0.727; p = 0.0058), and those who underwent biopsy (HR = 0.740; 95% CI: 0.463-1.182; p = 0.003), subtotal resection (STR) (HR = 0.490; 95% CI: 0.265-0.906; p = 0.0064), or gross total resection (GTR) (HR = 0.613; 95% CI: 0.292-1.287; p = 0.0003) had better prognoses in the postoperative chemotherapy group compared to the non-chemotherapy group. Conclusion POCT significantly improves the prognosis of PCNSL patients and identifies the characteristics of the benefiting population. This information aids clinical practitioners in designing personalized treatment plans for individuals and advancing precise treatment.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Conditional survival of elderly primary central nervous system lymphoma
    Qian, Hui
    Yang, Zhihao
    Cai, Linqiang
    Chen, Huawei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 13391 - 13401
  • [2] Epidemiologic Characteristics, Prognostic Factors, and Treatment Outcomes in Primary Central Nervous System Lymphoma: A SEER-Based Study
    Tang, Dongsheng
    Chen, Yue
    Shi, Yuye
    Tao, Hong
    Tao, Shandong
    Zhang, Quan'e
    Ding, Banghe
    He, Zhengmei
    Yu, Liang
    Wang, Chunling
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [3] Survival among patients with primary central nervous system lymphoma, 1973-2004
    Norden, Andrew D.
    Drappatz, Jan
    Wen, Patrick Y.
    Claus, Elizabeth B.
    JOURNAL OF NEURO-ONCOLOGY, 2011, 101 (03) : 487 - 493
  • [4] Prognostic model and treatment choices for patients with primary intracranial central nervous system lymphoma: A population-based study
    Jiang, Qingsong
    Zhan, Guoyong
    Jiang, Wenhong
    Xu, Yafeng
    Zheng, Guofu
    Jiang, Cai
    Lin, Dongdong
    Wang, Kang
    Zhu, Huiwu
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2023, 233
  • [5] Real-World Impact of Surgical Excision on Overall Survival in Primary Central Nervous System Lymphoma
    Deng, Xiangyang
    Xu, Xingxing
    Lin, Dongdong
    Zhang, Xiaojia
    Yu, Lisheng
    Sheng, Hansong
    Yin, Bo
    Zhang, Nu
    Lin, Jian
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [6] Primary treatment and recent survival trends in patients with primary diffuse large B-cell lymphoma of central nervous system, 1995-2016: A population-based SEER analysis
    Chen, Cui
    Sun, Peng
    Sun, Xiao-Qing
    Chen, Shao-Yong
    Yang, Hang
    Wang, Yu
    Li, Zhi-Ming
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (02) : 248 - 256
  • [7] Impact of Systemic and Radiation Therapy on Survival of Primary Central Nervous System Lymphoma
    Janopaul-Naylor, James Robert
    Patel, Jimmy S.
    Rupji, Manali
    Hoang, Kimberly Bojanowski
    Mccall, Neal Sean
    Qian, David C.
    Shoaf, Madison Lee
    Kothari, Shawn
    Olson, Jeffrey J.
    Shu, Hui-Kuo G.
    Voloschin, Alfredo
    Zhong, Jim
    Neill, Stewart G.
    Eaton, Bree
    CANCERS, 2025, 17 (04)
  • [8] (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study
    Collignon, A.
    Houillier, C.
    Ahle, G.
    Chinot, O.
    Choquet, S.
    Schmitt, A.
    Agape, P.
    Soussain, C.
    Hoang-Xuan, K.
    Tabouret, Emeline
    ANNALS OF HEMATOLOGY, 2019, 98 (04) : 915 - 922
  • [9] The Impact of Early Corticosteroid Pretreatment Before Initiation of Chemotherapy in Patients With Primary Central Nervous System Lymphoma
    Gessler, Florian
    Bernstock, Joshua D.
    Behmanesh, Bedjan
    Brunnberg, Uta
    Harter, Patrick
    Ye, Daniel
    Friedman, Gregory K.
    Hansmann, Martin-Leo
    Wagner, Marlies
    Seifert, Volker
    Weise, Lutz
    Marquardt, Gerhard
    NEUROSURGERY, 2019, 85 (02) : 264 - 272
  • [10] Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis
    Ollila, Thomas A.
    Taher, Rashida
    Moku, Prashanth
    Olszewski, Adam J.
    BLOOD ADVANCES, 2023, 7 (18) : 5470 - 5479